Three US states launch biotech seed funds

Article Abstract:

Pennsylvania, Indiana and New Jersey launched the seed of venture funds to invest in local life science startups and these funds will help to fill the 'development gap' that is the lack of money available to transform ideas into new companies which could eventually attract venture capitalist (VC) money. The development gap is widening because VCs are raising more money to invest in the biotech industry.

Research and Development in the Physical, Engineering, and Life Sciences, Financial management, New Jersey, Venture Capital Companies, Miscellaneous Intermediation, Investors, not elsewhere classified, Life Sciences, Indiana, Biotechnology industry, Biotechnology industries, Finance, Company investment, Investments, Company financing

---

Global biotech expansion taking cues from Bayh-Dole

Article Abstract:

The Bayh-Dole system has altered the US economy in relation to the global economy and the other countries are also planning to do a similar thing. The thoughts and rules of the Bayh-Dole system are very much distinct from that of the cultural and structural modifications which support the change in technology.

Government expenditures, Forecasts, trends, outlooks, Biological Product (except Diagnostic) Manufacturing, Molecular Biological Products, Forecasts and trends, Economic policy, Development and progression, Market trend/market analysis, Growth, Biotechnology, Company growth, Global economy, Cultural movements

---

Unlocking the money-making potential of RNAi

Article Abstract:

According to the Front Line Strategic Consulting the market for RNA interferene (RNAi) based products is estimated to be $38 million for 2003. The acceptance of RNAi-type technologies can be measured by the number of researchers using small interfering RNA (siRNA) to silence genes.

Commodity & service prices, Market share, Management dynamics, Management, Prices and rates, Biological products industry, Technology application, Gene expression, Company business management, Company market share, Company pricing policy, RNA interference

Similar abstracts:

• Abstracts: The number on biotech indexes. Putting biotech risk in its place. Going short on biotech
• Abstracts: Politics torpedo biotech as EU priority. Taiwan: biotech vision. Germany biotech gets second chance
• Abstracts: Diversifying in biotech. Does biotech M&A benefit investors?. Biotech IPOs: handle with care

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.